Treatment-Resistant Depression Management

Guideline Recommendations

The American College of Physicians recommends that all second-generation antidepressants demonstrate equivalent ultimate efficacy for major depressive disorder, with no clinically significant differences in response rates, remission rates, or quality of life improvements, and switching to a different class is the evidence-based approach rather than combining agents 1, 2
The American Academy of Family Physicians suggests that switching to bupropion, venlafaxine, or sertraline is a first-line strategy for treatment-resistant depression, with equivalent 25% remission rates shown in the STAR*D trial 3
The Mayo Clinic recommends duloxetine for comorbid pain, and mirtazapine for depression with prominent insomnia and pain, due to its sedation and appetite-stimulating effects 4, 1

The combination of duloxetine and mirtazapine may be considered only after exhausting guideline-recommended alternatives, and only in highly selected inpatient settings with close monitoring, for severe, chronic treatment-resistant depression that has failed multiple adequate trials, including switching strategies 4, 1
The Annals of Internal Medicine notes that mirtazapine monotherapy shows a faster onset of action (1-2 weeks) than SSRIs/SNRIs, and may be considered as an alternative to combination therapy 1, 5

The American Family Physician warns that the combination of duloxetine and mirtazapine carries a significant risk of serotonin syndrome due to dual serotonergic mechanisms, and recommends monitoring for tremor, diarrhea, delirium, neuromuscular rigidity, and hyperthermia 2
The Annals of Internal Medicine reports that 38% of patients will not respond and 54% will not achieve remission within 6-12 weeks, regardless of strategy chosen, and recommends setting realistic expectations and having contingency plans 1

The American College of Physicians recommends switching to a different class of antidepressant, such as bupropion, venlafaxine, or sertraline, which demonstrate equivalent 25% remission rates in treatment-resistant depression 6

The American College of Physicians suggests choosing bupropion if a patient experienced sexual dysfunction or weight gain on prior SSRIs, as augmentation studies show bupropion has lower discontinuation rates than buspirone 6, 7, 8
The American Academy of Pediatrics recommends considering bupropion if a patient has prominent fatigue or psychomotor retardation 9

The American College of Physicians recommends augmenting the new antidepressant with bupropion SR 150-300mg daily, as low-quality evidence shows augmentation with bupropion decreases depression severity more than buspirone, with lower discontinuation rates due to adverse events 7, 8
Cognitive behavioral therapy augmentation is equally effective as pharmacologic augmentation, with low-quality evidence showing no difference in response, remission, or depression severity 7, 8

The American Academy of Pediatrics recommends implementing a monitoring schedule, including in-person or telephone contact to assess early adverse effects and adherence at week 1, and weekly monitoring for suicidal ideation, behavioral activation, and treatment response at weeks 2-4 6, 9
At each contact, specifically assess ongoing depressive symptoms, suicide risk, adverse effects, adherence to treatment, and new environmental stressors 6, 9